Keystonemab – AI-driven scientific intelligence

How the power of Artificial Intelligence saves medicine developers decennia of work

Even though 90% of all clinical research for new medicine ends in a failure, these studies do gather useful data. They offer a solution while developing other medicine. Perhaps a rejected drug can successfully be used for another treatment, or to boost the effectiveness of other medicine. The problem: there are numerous scientific data. Combing through…

Keystonemab welcomes Nitin Shendre as new Chief Corporate Development Officer

Press Release: Sept. 30, 2022 – Utrecht, the Netherlands We are delighted to welcome Nitin as a seed investor and Chief Corporate Development Officer of Keystonemab. Nitin will actively help with developing Keystonemab’s corporate strategy and business relationships in high growth market including India. Nitin is a serial entrepreneur with focus on industrial real-estate since…

1 2 3